Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

Core Viewpoint - Investing in underperforming biotech stocks like CRISPR Therapeutics, Amgen, and Regeneron may present recovery opportunities despite their recent market losses [1][2]. Group 1: CRISPR Therapeutics - CRISPR Therapeutics specializes in gene editing and has developed Casgevy for sickle cell disease and transfusion-dependent beta-thalassemia, but is currently not generating significant revenue [3][4]. - The company is unprofitable, leading to skepticism about its prospects, yet Casgevy has substantial potential, especially in the Middle East with an estimated patient population of at least 58,000 [4][6]. - The FDA granted RMAT designation to CRISPR's CTX112 for B-cell malignancies, indicating promising early data and high unmet needs, which could enhance its market position [6][7]. Group 2: Amgen - Amgen's stock declined after phase 2 data for its weight loss candidate, MariTide, but the company remains a strong long-term investment due to its diverse product lineup, including Tepezza for thyroid eye disease [8][9]. - The company has over 50 ongoing clinical trials, indicating a robust pipeline for future growth, and has increased its dividend payouts by 201% over the past decade, currently offering a yield of about 3.3% [10][11]. - Despite facing challenges like patent cliffs, Amgen's strong underlying business and innovative capabilities position it well for long-term success [11]. Group 3: Regeneron Pharmaceuticals - Regeneron relies on Dupixent and Eylea for revenue growth, but Eylea faces competition from Roche's Vabysmo and Amgen's Pavblu, creating uncertainty in its medium-term prospects [12][13]. - Dupixent has gained a new indication for chronic obstructive pulmonary disease, expected to add several billion dollars in annual revenue, contributing to a total revenue of $3.79 billion, a 10% increase year-over-year [14]. - Regeneron is expanding its oncology business with Libtayo and has numerous clinical trials underway, aiming to offset potential revenue losses from Eylea through innovation [16].